Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $25.8 million.

  • Ultragenyx Pharmaceutical's Net Cash Flow rose 10777.52% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year decrease of 3507.37%. This contributed to the annual value of -$32.7 million for FY2024, which is 14022.2% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Net Cash Flow stood at $25.8 million for Q3 2025, which was up 10777.52% from $46.6 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Cash Flow ranged from a high of $368.5 million in Q2 2024 and a low of -$331.3 million during Q3 2024
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Net Cash Flow value was -$28.3 million (recorded in 2023), while the average stood at -$26.9 million.
  • Over the last 5 years, Ultragenyx Pharmaceutical's Net Cash Flow had its largest YoY gain of 216417.64% in 2024, and its largest YoY loss of 106889.4% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Net Cash Flow (Quarter) stood at $100.4 million in 2021, then crashed by 358.92% to -$260.1 million in 2022, then soared by 153.71% to $139.7 million in 2023, then crashed by 81.09% to $26.4 million in 2024, then fell by 2.49% to $25.8 million in 2025.
  • Its Net Cash Flow stands at $25.8 million for Q3 2025, versus $46.6 million for Q2 2025 and -$46.4 million for Q1 2025.